Critical signal transduction pathways in CLL

Asish K. Ghosh, Neil Elliot Kay

Research output: Chapter in Book/Report/Conference proceedingChapter

8 Citations (Scopus)

Abstract

Receptor tyrosine kinases (RTKs) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play a critical role in signal transduction in both normal and malignant cells. Besides B cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL), multiple RTKs have been reported to be constitutively active in CLL B cells, resulting in enhanced survival and resistance to apoptosis of the leukemic cells induced by chemotherapeutic agents. In addition to increased plasma levels of various types of cytokines/growth factors in CLL, we and others have detected that CLL B cells spontaneously produce multiple cytokines in vitro which may constitute an autocrine loop of RTK activation on the leukemic B cells. Moreover, aberrant expression and activation of non-RTKs, for example, Src/Syk kinases, induce resistance of the leukemic B cells to therapy. Based on current available knowledge, we detailed the impact of aberrant activities of various RTKs/non-RTKs on CLL B cell survival and the potential of using these signaling components as future therapeutic targets in CLL therapy.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages215-239
Number of pages25
Volume792
ISBN (Print)9781461480501
DOIs
StatePublished - 2013

Publication series

NameAdvances in Experimental Medicine and Biology
Volume792
ISSN (Print)00652598

Fingerprint

Signal transduction
B-Cell Chronic Lymphocytic Leukemia
Signal Transduction
Cells
Receptor Protein-Tyrosine Kinases
B-Lymphocytes
Protein-Tyrosine Kinases
Phosphotransferases
Chemical activation
Cytokines
src-Family Kinases
Cell Surface Receptors
Cell- and Tissue-Based Therapy
Cell Survival
Intercellular Signaling Peptides and Proteins
Apoptosis
Plasmas
Therapeutics

Keywords

  • Apoptosis
  • CLL
  • Kinase inhibitor
  • Non-RTK
  • RTK
  • Signal transduction
  • Therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Ghosh, A. K., & Kay, N. E. (2013). Critical signal transduction pathways in CLL. In Advances in Experimental Medicine and Biology (Vol. 792, pp. 215-239). (Advances in Experimental Medicine and Biology; Vol. 792). Springer New York LLC. https://doi.org/10.1007/978-1-4614-8051-8_10

Critical signal transduction pathways in CLL. / Ghosh, Asish K.; Kay, Neil Elliot.

Advances in Experimental Medicine and Biology. Vol. 792 Springer New York LLC, 2013. p. 215-239 (Advances in Experimental Medicine and Biology; Vol. 792).

Research output: Chapter in Book/Report/Conference proceedingChapter

Ghosh, AK & Kay, NE 2013, Critical signal transduction pathways in CLL. in Advances in Experimental Medicine and Biology. vol. 792, Advances in Experimental Medicine and Biology, vol. 792, Springer New York LLC, pp. 215-239. https://doi.org/10.1007/978-1-4614-8051-8_10
Ghosh AK, Kay NE. Critical signal transduction pathways in CLL. In Advances in Experimental Medicine and Biology. Vol. 792. Springer New York LLC. 2013. p. 215-239. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4614-8051-8_10
Ghosh, Asish K. ; Kay, Neil Elliot. / Critical signal transduction pathways in CLL. Advances in Experimental Medicine and Biology. Vol. 792 Springer New York LLC, 2013. pp. 215-239 (Advances in Experimental Medicine and Biology).
@inbook{ad4f3c9a2bec4e6d98a571264ef2de2d,
title = "Critical signal transduction pathways in CLL",
abstract = "Receptor tyrosine kinases (RTKs) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play a critical role in signal transduction in both normal and malignant cells. Besides B cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL), multiple RTKs have been reported to be constitutively active in CLL B cells, resulting in enhanced survival and resistance to apoptosis of the leukemic cells induced by chemotherapeutic agents. In addition to increased plasma levels of various types of cytokines/growth factors in CLL, we and others have detected that CLL B cells spontaneously produce multiple cytokines in vitro which may constitute an autocrine loop of RTK activation on the leukemic B cells. Moreover, aberrant expression and activation of non-RTKs, for example, Src/Syk kinases, induce resistance of the leukemic B cells to therapy. Based on current available knowledge, we detailed the impact of aberrant activities of various RTKs/non-RTKs on CLL B cell survival and the potential of using these signaling components as future therapeutic targets in CLL therapy.",
keywords = "Apoptosis, CLL, Kinase inhibitor, Non-RTK, RTK, Signal transduction, Therapy",
author = "Ghosh, {Asish K.} and Kay, {Neil Elliot}",
year = "2013",
doi = "10.1007/978-1-4614-8051-8_10",
language = "English (US)",
isbn = "9781461480501",
volume = "792",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "215--239",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Critical signal transduction pathways in CLL

AU - Ghosh, Asish K.

AU - Kay, Neil Elliot

PY - 2013

Y1 - 2013

N2 - Receptor tyrosine kinases (RTKs) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play a critical role in signal transduction in both normal and malignant cells. Besides B cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL), multiple RTKs have been reported to be constitutively active in CLL B cells, resulting in enhanced survival and resistance to apoptosis of the leukemic cells induced by chemotherapeutic agents. In addition to increased plasma levels of various types of cytokines/growth factors in CLL, we and others have detected that CLL B cells spontaneously produce multiple cytokines in vitro which may constitute an autocrine loop of RTK activation on the leukemic B cells. Moreover, aberrant expression and activation of non-RTKs, for example, Src/Syk kinases, induce resistance of the leukemic B cells to therapy. Based on current available knowledge, we detailed the impact of aberrant activities of various RTKs/non-RTKs on CLL B cell survival and the potential of using these signaling components as future therapeutic targets in CLL therapy.

AB - Receptor tyrosine kinases (RTKs) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play a critical role in signal transduction in both normal and malignant cells. Besides B cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL), multiple RTKs have been reported to be constitutively active in CLL B cells, resulting in enhanced survival and resistance to apoptosis of the leukemic cells induced by chemotherapeutic agents. In addition to increased plasma levels of various types of cytokines/growth factors in CLL, we and others have detected that CLL B cells spontaneously produce multiple cytokines in vitro which may constitute an autocrine loop of RTK activation on the leukemic B cells. Moreover, aberrant expression and activation of non-RTKs, for example, Src/Syk kinases, induce resistance of the leukemic B cells to therapy. Based on current available knowledge, we detailed the impact of aberrant activities of various RTKs/non-RTKs on CLL B cell survival and the potential of using these signaling components as future therapeutic targets in CLL therapy.

KW - Apoptosis

KW - CLL

KW - Kinase inhibitor

KW - Non-RTK

KW - RTK

KW - Signal transduction

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84934439133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934439133&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-8051-8_10

DO - 10.1007/978-1-4614-8051-8_10

M3 - Chapter

AN - SCOPUS:84934439133

SN - 9781461480501

VL - 792

T3 - Advances in Experimental Medicine and Biology

SP - 215

EP - 239

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -